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LETTER TO THE EDITOR
Are Low- and Middle-Income Countries Becoming the
Victim of Western Debates About Breast Screening?
To the Editor:
Recently, two important initiatives took place to
further increase quality of breast cancer (BC) screen-
ing and treatment, also in other than high-income
countries. In Batumi, Georgia, the 1st International
Black Sea Conference on cervical and BC screening
was held on 10th and 11th September 2009 with
participants from Armenia, Azerbaijan, Bulgaria,
Georgia, Moldova, Romania, Turkey, and Ukraine.
By exchanging experiences, ideas and the scientific
evidence available, plans to further improve imple-
mentation of breast (and cervical) cancer screening
were debated and formed.
From 24–27 October 2009, the 15th Annual Multi-
disciplinary Symposium on Breast Disease was held in
Cairo with a special summit on health care disparities
in developing countries. With thousands of people
running the ‘‘race for cure’’ at the Giza pyramids,
around 600 participants at the symposium, the pres-
ence of ambassador Nancy Brinker of the Susan G
Koomen For The Cure and her interview for CNN,
the importance of BC prevention got international and
high profile attention again. Not least to say, due to
the excellent organization and programme directed by
Shahla Masood, the editor of The Breast Journal.
The programme reflected nicely the integrated
approach in BC care: primary prevention, screening
and treatment, and palliative care, with excellent
speakers from high-, middle- and low-income coun-
tries. However, the evidence on and fact sheet about
BC screening seemed overwhelmed, again, by negative
sounds, either called critical issues, challenges or
controversies, as was aired recently again both on this
and the other side of the Atlantic (1–3).
Screening has always been highly controversial,
partly because the procedure is for seemingly healthy
people, for whom the benefit should be clear. Evi-
dence of this benefit is, however, for the group as a
whole. At the individual level, prediction of who will
benefit and who will suffer more harm than good is
impossible. The balance between favorable and unfa-
vorable effects is delicate (4).
Of course, it is not likely to involve large-scale
mammography as a screening test in low-resources
countries, but the debate about mammography screen-
ing in Western countries seemed to question and lead
to disbelief about the benefits of BC screening in gen-
eral. That is simply wrong.
Whether earlier detection and treatment of BC
result in health benefits was hypothesized in the 1960s
(5). Large clinical series then showed that for women
extensively treated but with relatively large tumors the
chance of distant metastases was significantly higher
even 25 years after primary treatment (6). Horak
showed the biological concept of this: with growth of
the tumor, angiogenesis increases with increasing
chances of tumor spread to lymph nodes and beyond
(7). Removal of the tumor before such critical points
of angiogenesis might then mean a higher cure rate.
Randomised controlled trials on mammography
screening during 1960–1980 confirmed the benefits of
earlier detection and treatment by showing a 25%
reduction in BC mortality in invited women aged 50
and over compared to a control group (8). Also, in
practice, numerous case–control studies showed that
screened women have a 30–40% reduced risk in dying
from the disease (9), although case–control studies of
screening may be biased by the fact that women
who have been screened may have been self-selected
(showing a favorable outcome independent of screen-
ing). This hampers standard evaluations when large-
scale breast screen programmes are running, but we
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elegantly showed that in the Netherlands the start of
screening in the municipality changed the annual
increase in BC mortality from 0.3 per 100,000
increase per year towards a 1.7 per 100,000 decrease
per year (10; Fig. 1). Model exercises showed that
roughly 50% of the decline in BC mortality in the US
was likely to be due to the mammography dissemina-
tion between 1975 and 2000 (11).
So, there should be no doubt that high quality mam-
mography screening (followed by treatment of early
stage cancer) substantially reduces BC mortality in a
population. Unfortunately, trials on teaching breast self
examination have failed to show a beneficial effect on
BC mortality (8). For low- and middle-income coun-
tries clinical breast examination (CBE) may be an
appropriate alternative to mammography. There is
only one randomised controlled trial reported, the
Canadian National Breast Screening Study that invited
randomised women for clinical breast exams per-
formed by highly trained nurses and the other group
for clinical breast exams and mammography (12).
Since the trial did not have a control arm without
screening tests offered, one has to estimate to what the
stages (and stage shift) produced by the clinical breast
exams compares to. By detailed mathematical model-
ing Rijnsburger estimated the CBEs might have pro-
duced a 20.5% BC mortality difference compared to a
(nonobserved) control situation without screening (13).
In many middle-income countries BC incidence is
steadily increasing due to aging of the population and
a remarkable change in risk factors (14). At the same
time, BC is often diagnosed at a late stage. So it
means that two prerequisites of considering screening
and earlier detection are met.
Especially this worse clinical stage distribution
may be one of the main reasons why breast screen-
ing, e.g., by clinical exams may still be cost-effective
in low-resource and low-incidence countries. The
shift attainable by screening may result in important
Figure 1. Relative rates of breast cancer by year since introduction of screening in municipalities for age groups 55–74 years in the Neth-
erlands (Otto et al., Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a
systematic review. Lancet 2003;361(9367):1411–17; reproduced with permission from Elsevier).
Figure 2. Differential costs and effects of breast cancer screening
programs, discounted at 3% per year (based on Okonkwo et al.,
JNCI 2009). The dashed line indicates a cost-effectiveness ratio of
Int.$1000 per life year saved, and the solid line indicates the effi-
cient frontier. The numbers refer to the programs in the original
paper (Okonkwo et al., JNCI 2009).
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health benefits, if high quality early treatment is
available. For India, we found that screening by
clinical breast exams every 2 years for women aged
40–60 might lead to a 16.3% reduction in BC mor-
tality at 6.6 million Int.$ cost (15). Although there is
not one guideline applicable to all countries, CBE
screening should seriously be considered in many
countries. Figure 2 shows the so-called efficient fron-
tier of breast screen scenarios in India. It shows that
programmes with clinical breast exams are cost-effec-
tive. This does not mean advising inferior technology
for low-income countries; this means achieving
important health benefits for the resources available.
Of course, the mortality results in the running India
trial are eagerly awaited (16), but in the mean time
pilot studies performing CBE screening could be
gradually implemented. Any new feasible technology
or policy changes could perhaps be built on that.
Many steps have to be taken still, both in break-
ing cultural barriers, in increasing knowledge and
fighting misconceptions. There are unfortunately
numerous misconceptions: some think the breast is a
vital organ and some think cancer is a contagious
disease. There are cultural barriers, e.g., in the cos-
tumes and clothing hiding any clear visible abnormal-
ities, in the fear women will loose their husbands
when loosing their breast and therefore income,
women feeling not being a woman anymore and in
practical issues like transportation to a screening cen-
ter as a woman. Unfortunately, also some health care
providers are still not equipped both physically nor
knowledgeable.
It will be far from easy to start breast screening by
clinical breast exams in low-resource countries. It will
be challenging to use the culture positively. Tailored
out-reach community services, one-stop clinics and
emphasis on both public education and health care
professionals education will be crucial to ‘‘win the
race’’. These initiatives are crucial to pave the roads.
And let developing countries not make the same mis-
take to be confused and stopped in their progress by
Western debates about the benefits of breast screening.
When you don’t know where you are going,
every road will take you there (adapted from Alice in
Wonderland).
Harry J. de Koning, MD, PhD
Department of Public Health,
Erasmus MC, University Medical Center Rotterdam,
PO Box 2040, 3000 CA Rotterdam, the Netherlands
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